全文获取类型
收费全文 | 25679篇 |
免费 | 1806篇 |
国内免费 | 138篇 |
专业分类
耳鼻咽喉 | 90篇 |
儿科学 | 1483篇 |
妇产科学 | 604篇 |
基础医学 | 2211篇 |
口腔科学 | 110篇 |
临床医学 | 2497篇 |
内科学 | 7836篇 |
皮肤病学 | 462篇 |
神经病学 | 2006篇 |
特种医学 | 224篇 |
外科学 | 2945篇 |
综合类 | 606篇 |
现状与发展 | 1篇 |
一般理论 | 6篇 |
预防医学 | 2222篇 |
眼科学 | 954篇 |
药学 | 1115篇 |
2篇 | |
中国医学 | 50篇 |
肿瘤学 | 2199篇 |
出版年
2024年 | 41篇 |
2023年 | 247篇 |
2022年 | 229篇 |
2021年 | 346篇 |
2020年 | 338篇 |
2019年 | 119篇 |
2018年 | 466篇 |
2017年 | 495篇 |
2016年 | 550篇 |
2015年 | 534篇 |
2014年 | 445篇 |
2013年 | 709篇 |
2012年 | 1993篇 |
2011年 | 2270篇 |
2010年 | 795篇 |
2009年 | 772篇 |
2008年 | 2434篇 |
2007年 | 2314篇 |
2006年 | 2001篇 |
2005年 | 2088篇 |
2004年 | 2042篇 |
2003年 | 2079篇 |
2002年 | 1673篇 |
2001年 | 1249篇 |
2000年 | 282篇 |
1999年 | 137篇 |
1998年 | 199篇 |
1997年 | 116篇 |
1996年 | 90篇 |
1995年 | 57篇 |
1994年 | 71篇 |
1993年 | 36篇 |
1992年 | 41篇 |
1991年 | 32篇 |
1990年 | 37篇 |
1989年 | 36篇 |
1988年 | 36篇 |
1987年 | 38篇 |
1986年 | 33篇 |
1985年 | 24篇 |
1984年 | 24篇 |
1983年 | 11篇 |
1982年 | 17篇 |
1981年 | 19篇 |
1980年 | 12篇 |
1979年 | 7篇 |
1978年 | 6篇 |
1974年 | 4篇 |
1973年 | 3篇 |
1970年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
101.
Guidelines for treatment of ulcerative colitis in children 总被引:2,自引:0,他引:2
Takeshi Tomomasa Akio Kobayashi Kousuke Ushijima Keiichi Uchida Seiichi Kagimoto Toshiaki Shimizu Hitoshi Tajiri Takuhiro Tahara Atushi Yoden for the Working Group of the Japanese Society for Pediatric Gastroenterology Hepatology Nutrition 《Pediatrics international》2004,46(4):494-496
This paper introduces the guidelines for treatment of ulcerative colitis in children, created by the working group of the Japanese Society for Pediatric Gastroenterology, Hepatology and Nutrition (Chair: Yuichiro Yamashiro) and the Japanese Society for Pediatric Inflammatory Bowel Disease (IBD) (Chair: Akio Kobayashi). The ideas of the working group, with regard to the fundamental differences in medical treatment between children and adults, included: (1) for children, intensive medical treatment including appropriate systemic management is important during the acute phase of illness. (2) Treatment with steroids, which can cause growth disturbances, should not be continued for long periods of time. (3) Pulsed steroid therapy, selective removal of blood cells, and intravenous infusion of cyclosporin should be included in the therapeutic option for severe and fluminant cases. 相似文献
102.
103.
104.
Effect of neighbourhood income and maternal education on birth outcomes: a population-based study 总被引:5,自引:0,他引:5 下载免费PDF全文
105.
106.
107.
108.
Takaaki Konuma Shohei Mizuno Tadakazu Kondo Yasuyuki Arai Naoyuki Uchida Satoshi Takahashi Masatsugu Tanaka Takuro Kuriyama Shigesaburo Miyakoshi Makoto Onizuka Shuichi Ota Yasuhiro Sugio Yasushi Kouzai Toshiro Kawakita Hikaru Kobayashi Yukiyasu Ozawa Takafumi Kimura Tatsuo Ichinohe Yoshiko Atsuta Masamitsu Yanada for the Adult Acute Myeloid Leukemia Working Group of the Japanese Society for Transplantation Cellular Therapy 《Blood cancer journal》2022,12(5)
Unrelated cord blood transplantation (CBT) is an alternative curative option for adult patients with acute myeloid leukemia (AML) who need allogeneic hematopoietic cell transplantation (HCT) but lack an HLA-matched related or unrelated donor. However, large-scale data are lacking on CBT outcomes for unselected adult AML. To investigate the trends of survival and engraftment after CBT over the past 22 years, we retrospectively evaluated the data of patients with AML in Japan according to the time period of CBT (1998–2007 vs 2008–2013 vs 2014–2019). A total of 5504 patients who received single-unit CBT as first allogeneic HCT for AML were included. Overall survival (OS) at 2 years significantly improved over time. The improved OS among patients in ≥ complete remission (CR)3 and active disease at CBT was mainly due to a reduction of relapse-related mortality, whereas among patients in first or second CR at CBT, this was due mainly to a reduction of non-relapse mortality. The trends of neutrophil engraftment also improved over time. This experience demonstrated that the survival and engraftment rate after CBT for this group has improved over the past 22 years.Subject terms: Acute myeloid leukaemia, Cancer immunotherapy 相似文献
109.
Dipesh E. Patel Phillippa M. Cumberland Bronwen C. Walters Joseph Abbott John Brookes Beth Edmunds Peng Tee Khaw Ian Christopher Lloyd Maria Papadopoulos Velota Sung Mario Cortina-Borja Jugnoo S. Rahi For the OPTIC Study Group 《Eye (London, England)》2022,36(6):1281
BackgroundPerimetry is important in the management of children with glaucoma, but there is limited evidence-based guidance on its use. We report an expert consensus-based study to update guidance and identify areas requiring further research.MethodsExperts were invited to participate in a modified Delphi consensus process. Panel selection was based on clinical experience of managing children with glaucoma and UK-based training to minimise diversity of view due to healthcare setting. Questionnaires were delivered electronically, and analysed to establish ‘agreement’. Divergence of opinions was investigated and resolved where possible through further iterations.Results7/9 experts invited agreed to participate. Consensus (≥5/7 (71%) in agreement) was achieved for 21/26 (80.8%) items in 2 rounds, generating recommendations to start perimetry from approximately 7 years of age (IQR: 6.75–7.25), and use qualitative methods in conjunction with automated reliability indices to assess test quality. There was a lack of agreement about defining progressive visual field (VF) loss and methods for implementing perimetry longitudinally.Panel members highlighted the importance of informing decisions based upon individual circumstances—from gauging maturity/capability when selecting tests and interpreting outcomes, to accounting for specific clinical features (e.g. poor IOP control and/or suspected progressive VF loss) when making decisions about frequency of testing.ConclusionsThere is commonality of expert views in relation to implementing perimetry and interpreting test quality in the management of children with glaucoma. However, there remains a lack of agreement about defining progressive VF loss, and utilising perimetry over an individuals’ lifetime, highlighting the need for further research.Subject terms: Paediatrics, Glaucoma 相似文献
110.
Donatella Panatto Andrea Orsi Bianca Bruzzone Valentina Ricucci Guido Fedele Giorgio Reiner Nadia Giarratana Alexander Domnich Giancarlo Icardi STX Study Group 《Viruses》2022,14(5)
Sentinox (STX) is an acid-oxidizing solution containing hypochlorous acid in spray whose virucidal activity against SARS-CoV-2 has been demonstrated. In this paper, results of a randomized controlled trial (RCT) on the efficacy of STX in reducing viral load in mild COVID-19 patients () and a complementary in vitro study on its activity against different respiratory viruses are reported. In the RCT, 57 patients were randomized (1:1:1) to receive STX three (STX-3) or five (STX-5) times/day plus standard therapy or standard therapy only (controls). Compared with controls, the log10 load reduction in groups STX-3 and STX-5 was 1.02 (p = 0.14) and 0.18 (p = 0.80), respectively. These results were likely driven by outliers with extreme baseline viral loads. When considering subjects with baseline cycle threshold values of 20–30, STX-3 showed a significant (p = 0.016) 2.01 log10 reduction. The proportion of subjects that turned negative by the end of treatment (day 5) was significantly higher in the STX-3 group than in controls, suggesting a shorter virus clearance time. STX was safe and well-tolerated. In the in vitro study, ≥99.9% reduction in titers against common respiratory viruses was observed. STX is a safe device with large virucidal spectrum and may reduce viral loads in mild COVID-19 patients. NCT04909996相似文献